Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
doxorubicin liposomal + melphalan + bortezomib
- Development stage
- Unknown
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
This is a combination therapy regimen used in the treatment of multiple myeloma. It combines three active agents: pegylated liposomal doxorubicin (PLD, also known as Doxil), melphalan, and bortezomib (Velcade). This combination has been studied particularly in elderly newly diagnosed multiple myeloma patients. The regimen typically involves induction therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone followed by melphalan conditioning for stem cell transplantation.
- Other names
- pegylated liposomal doxorubicin + melphalan + bortezomibPLD + melphalan + bortezomib
02
Targets
26S proteasomeDNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on doxorubicin liposomal + melphalan + bortezomib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on doxorubicin liposomal + melphalan + bortezomib.